Bispecific Antibodies Are Reshaping Multiple Myeloma Care: Prerna Mewawalla, MD

Why It Matters

The high efficacy and immediate availability of bispecific antibodies provide clinicians with a flexible, less toxic option that can improve outcomes for multiple myeloma patients who cannot wait for CAR‑T manufacturing or who have neurological constraints.

Key Takeaways

• Bispecific antibodies achieve up to 80% response rates in early relapses
• They target BCMA, GPRC5D, or FcRH5 while engaging CD3 T cells
• Off‑the‑shelf format enables rapid treatment start versus CAR‑T manufacturing
• Lower severe neurotoxicity expands use for patients with neurological issues
• Choice between CAR‑T and bispecifics hinges on fitness and disease speed

Pulse Analysis

Bispecific antibodies have swiftly moved to the forefront of multiple myeloma therapy, leveraging a dual‑binding design that simultaneously latches onto a tumor‑associated antigen such as BCMA, GPRC5D, or FcRH5 and the CD3 receptor on T cells. This engineered bridge redirects cytotoxic T‑cells to malignant plasma cells, triggering cytokine release and cell death. Clinical data now show response rates climbing from historic 30 % in refractory settings to as high as 80 % when these agents are introduced earlier in the relapse cascade, reshaping expectations for disease control.

The off‑the‑shelf nature of bispecifics contrasts sharply with autologous CAR‑T products, which require weeks of manufacturing and a hospital stay for lymphodepletion and infusion. For patients with aggressive progression, the ability to start therapy within days can be decisive. Moreover, bispecifics carry a more favorable neurotoxicity profile, making them suitable for individuals with pre‑existing neurological deficits or limited mobility. Clinicians therefore weigh patient fitness, disease kinetics, and logistical constraints when sequencing CAR‑T and bispecific options.

Looking ahead, the pipeline is expanding beyond BCMA to novel targets, promising even broader applicability across plasma‑cell disorders. Pharmaceutical firms are investing heavily in next‑generation bispecific formats that aim to improve potency while reducing cytokine release syndrome. As payer frameworks adapt to these high‑cost, high‑value therapies, market analysts anticipate accelerated adoption and potential shifts in standard‑of‑care algorithms. Ultimately, the convergence of rapid deployment, robust efficacy, and manageable safety positions bispecific antibodies as a cornerstone of future myeloma treatment strategies.